Only approximately 10% of genetically unselected patients with chemorefractory metastatic
colorectal cancer experience tumor regression when treated with the anti-epidermal growth …

Abstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of
great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) …

Epidermal growth factor receptor (EGFR) is a well-exploited therapeutic target in metastatic
colorectal cancer (mCRC). Unfortunately, not all patients benefit from current EGFR …

Integrated analysis of genomes, transcriptomes, proteomes and drug responses of cancer
cell lines (CCLs) is an emerging approach to uncover molecular mechanisms of drug action …

The tumor microenvironment (TME) represents a milieu enabling cancer cells to develop
malignant properties, while concerted interactions between cancer and stromal cells …

Purpose: EphA2 receptor is involved in multiple cross-talks with other cellular networks,
including EGFR, FAK, and VEGF pathways, with which it collaborates to stimulate cell …

The ephrin type‐A 2 receptor tyrosine kinase (EPHA2) is involved in the development and
progression of various cancer types, including colorectal cancer (CRC). There is also …

Tyrosine kinase inhibitors (TKIs) have become an important therapeutic option for treating
several forms of cancer. Gefitinib, an inhibitor of the epidermal growth factor receptor …

The ephrin type‐A receptor 2 (EPHA2) kinase belongs to the largest family of receptor
tyrosine kinases. There are several indications of an involvement of EPHA2 in the …

Purpose: Accumulating analyses of pro-oncogenic molecular mechanisms triggered a rapid
development of targeted cancer therapies. Although many of these treatments produce …